ライフサイエンスコーパス: dyslipidaemia

1 46 for hypertension; p(interaction)=0.31 for dyslipidaemia).

2 diseases such as diabetes, hypertension, and dyslipidaemia.

3 diabetes mellitus (T2DM), hypertension, and dyslipidaemia.

4 or at least 27 kg/m(2) with hypertension or dyslipidaemia.

5 fied by sex, age, diabetes, hypertension and dyslipidaemia.

6 sence of hypertension, diabetes mellitus and dyslipidaemia.

7 smoking, diabetes mellitus, hypertension and dyslipidaemia.

8 might further revolutionize our treatment of dyslipidaemia.

9 ge, sex, hypertension, diabetes mellitus and dyslipidaemia.

10 idities such as hypertension and atherogenic dyslipidaemia.

11 therogenic lipoproteins in adults with mixed dyslipidaemia.

12 sensitivity, increased fat accumulation and dyslipidaemia.

13 was reduced in a sample from a patient with dyslipidaemia.

14 ndently associated with maternal obesity and dyslipidaemia.

15 in versus pravastatin in adults with HIV and dyslipidaemia.

16 ection and atherosclerosis in the context of dyslipidaemia.

17 ds and apolipoproteins in patients with mild dyslipidaemia.

18 ETP) inhibitor TA-8995 in patients with mild dyslipidaemia.

19 vious phase 1 and 2 studies of patients with dyslipidaemia.

20 ce of physical activity for individuals with dyslipidaemia.

21 e/nonalcoholic fatty liver disease/metabolic dyslipidaemia.

22 nalcoholic fatty liver disease and metabolic dyslipidaemia.

23 sive genes and causes insulin resistance and dyslipidaemia.

24 d a potential new mechanism for treatment of dyslipidaemia.

25 9] mg/dL) decrease in LDL-C in patients with dyslipidaemia.

26 th policy for the care of patients with rare dyslipidaemias.

27 of rare lipoprotein disorders and associated dyslipidaemias.

28 diac deaths occur in people with atherogenic dyslipidaemias.

29 d a high prevalence of hypertension (24.8%), dyslipidaemia (17.5%), and diabetes (15.3%).

30 1.25-2.56), diabetes (2.31, 1.61-3.31), and dyslipidaemia (2.07, 1.01-4.26) were independent predict

31 central obesity, diabetes, hypertension, and dyslipidaemia, 26.7% (26.2-27.2) had one, 30.2% (29.7-30

32 with insulin resistance, hyperglycaemia and dyslipidaemia(3-7), aberrant non-essential amino acid (N

33 were vitamin D deficiency (428 of 690, 62%), dyslipidaemia (373, 50.1%), hypertension (157, 21.5%), d

34 essure (27/57 [47%] vs 9/55 [16%]; p=0.001), dyslipidaemia (48/56 [86%] vs 21/55 [38%]; p<0.0001), an

35 Comorbidities included hypertension (89%), dyslipidaemia (87%), Type 2 diabetes (48%), and chronic

36 advances have been made in the treatment of dyslipidaemia, a major risk factor for atherosclerotic c

37 ma (AIP) is a novel biomarker of atherogenic dyslipidaemia (AD), but its relationship with cardiac ad

38 nd 1435 [27.4%] female) were included in the dyslipidaemia analysis.

39 rtension associates with insulin resistance, dyslipidaemia and abdominal obesity, the identification

40 n syndromes associated with type 2 diabetes, dyslipidaemia and associated cardiac, renal and hepatic

41 Dyslipidaemia and autoimmune diseases were significantly

42 lic parameters including insulin resistance, dyslipidaemia and body mass index are increasingly recog

43 ns are commonly prescribed for management of dyslipidaemia and cardiovascular disease.

44 ntion in the setting of obesity, atherogenic dyslipidaemia and chronic kidney disease.

45 , hyperuricosuria, spontaneous hypertension, dyslipidaemia and elevated body fat.

46 ACLY is also a target against dyslipidaemia and hepatic steatosis, with a compound cur

47 Such in utero androgen excess recreated the dyslipidaemia and hormonal profile observed in sons of P

48 iabetic peripheral neuropathy is linked with dyslipidaemia and hyperglycaemia(4), the contribution of

49 by reducing fat mass and markedly improving dyslipidaemia and hyperglycaemia.

50 using waist circumference), hyperglycaemia, dyslipidaemia and hypertension, highlighting the need fo

51 ate are reasonable second-line therapies for dyslipidaemia and in diabetes, and well tolerated in com

52 ate are reasonable second-line therapies for dyslipidaemia and in diabetes.

53 ins of eating behaviour, energy expenditure, dyslipidaemia and insulin resistance suggest that coordi

54 e cardiomyopathy is multifactorial, diabetic dyslipidaemia and intramyocardial lipid accumulation are

55 xcess adiposity, impaired glycaemic control, dyslipidaemia and moderate hypertension.

56 evidence is less certain for other types of dyslipidaemia and other cardiovascular risk factors, inc

57 seases share many common features, including dyslipidaemia and transaminitis.

58 n 400 mg reduced apoB in patients with mixed dyslipidaemia and was generally well tolerated.

59 nifestations of disordered lipid metabolism (dyslipidaemia) and its management.

60 6.7) for hypertension, 34.5% (34.0-35.0) for dyslipidaemia, and 18.6% (18.2-19.0) for metabolic syndr

61 , 31% had pre-hypertension/hypertension, 69% dyslipidaemia, and 25% abnormal liver function.

62 ication, including for children with genetic dyslipidaemia, and are one of the most widely prescribed

63 , such as hypertension, diabetes, smoking or dyslipidaemia, and are similarly affected by systemic in

64 heir risk factors-particularly hypertension, dyslipidaemia, and diabetes-have become an increasing co

65 s, treatment, and control of blood pressure, dyslipidaemia, and glycaemia among people with diabetes

66 ion, and control targets for blood pressure, dyslipidaemia, and glycaemia recommended by WHO guidelin

67 abetes, MASH, hypertension, CKD, atherogenic dyslipidaemia, and heart failure.

68 e include hyperglycaemia, abdominal obesity, dyslipidaemia, and high blood pressure.

69 abdominal obesity, systemic inflammation and dyslipidaemia, and how they contribute to the clinical m

70 of weight gain, such as insulin resistance, dyslipidaemia, and hypertension.

71 The metabolic dysfunction, dyslipidaemia, and inflammation caused by obesity contri

72 over adulthood in the risks of hypertension, dyslipidaemia, and preclinical and clinical cardiovascul

73 e hyperinsulinaemia, insulin resistance, and dyslipidaemia, and the syndrome is associated with great

74 Improving the identification of primary dyslipidaemias, and understanding disparities in ascerta

75 nalcoholic fatty liver disease and metabolic dyslipidaemia are inextricably linked and need to be con

76 PURPOSE OF REVIEW: Dyslipidaemias are noted in all stages of chronic kidney

77 Metabolic syndrome, abdominal obesity and dyslipidaemia, are strongly associated with polyneuropat

78 ings identify systemic serine deficiency and dyslipidaemia as novel risk factors for peripheral neuro

79 ging cholesterol metabolism and diet induced dyslipidaemia, as well as insulin sensitivity in metabol

80 Dyslipidaemia associated with increased JCL (Exp(B)=1.30

81 isk factors (ie, hypertension, diabetes, and dyslipidaemia) associated with health-related mortality

82 enrolled adults (aged >=18 years) with mixed dyslipidaemia at 41 clinical research units across seven

83 rary non-INSTI, did not have hypertension or dyslipidaemia at baseline, and had baseline and at least

84 hypertensive levels especially in an ApoeKO dyslipidaemia background.

85 emains a major global health challenge, with dyslipidaemia being a key modifiable risk factor.

86 Mixed dyslipidaemia, characterised by elevated concentrations

87 that the pathogenic molecular mechanisms of dyslipidaemias contribute directly to arrhythmogenesis.

88 Univariate analysis identified a history of dyslipidaemia, coronary artery disease, diastolic blood

89 and two or more comorbidities (hypertension, dyslipidaemia, diabetes or prediabetes, or abdominal obe

90 increasing BMI and risk of hypertension and dyslipidaemia did not differ between participants receiv

91 ess include central obesity, hyperglycaemia, dyslipidaemia, electrolyte abnormalities and hypertensio

92 baseline until the earliest hypertension or dyslipidaemia event, their last visit, or Dec 31, 2021,

93 outcomes were incidence of hypertension and dyslipidaemia, for which we used multivariable Poisson r

94 tures induced by high-fat diet (HF), such as dyslipidaemia, glucose intolerance and hypertension.

95 syndrome' - obesity, insulin resistance and dyslipidaemia -- has conspired to produce a worldwide ep

96 ted adverse metabolic effects, which include dyslipidaemia, hepatic steatosis and impaired glucose to

97 nts with a significant degree of atherogenic dyslipidaemia (high triglycerides and low HDL-cholestero

98 Mouse models with predisposition to dyslipidaemia housed at thermoneutrality and fed a high-

99 murine model of FH transiently corrected the dyslipidaemia; however, humoral and cellular immune resp

100 peutic effect on obesity, hyperglycaemia and dyslipidaemia; however, its effect on NAFLD has yet to b

101 or drug target perturbation in hypertension, dyslipidaemia, hyperglycaemia and obesity.

102 ) are established agents in the treatment of dyslipidaemia, hyperglycaemia, and insulin resistance.

103 g for insulin resistant T2DM patients having dyslipidaemia, hypertension or history of cardiovascular

104 vascular (CV) risk factors (SMuRFs-diabetes, dyslipidaemia, hypertension, and smoking) presenting wit

105 iated conditions such as insulin resistance, dyslipidaemia, hypertension, hypertriglyceridemia, obesi

106 inked to many of the same risk factors (e.g. dyslipidaemia, hypertension, tobacco use, diabetes, and

107 hed for age, sex, hypertension, diabetes and dyslipidaemia in a 1:5 ratio.

108 Dyslipidaemia in adolescence tracks into adulthood and i

109 , insulin resistance, glucose metabolism and dyslipidaemia in Alstrom syndrome will be discussed as w

110 glucose intolerance, insulin resistance and dyslipidaemia in mice.

111 dence rate ratios (IRRs) of hypertension and dyslipidaemia in people receiving INSTIs, tenofovir alaf

112 atin as a preferred drug in the treatment of dyslipidaemia in people with HIV.

113 ectively reverse obesity, hyperglycaemia and dyslipidaemia in rodent models of metabolic disease.

114 rations to skin lipid profiles coincide with dyslipidaemia in serum.

115 c disease component (hypertension, diabetes, dyslipidaemia) in the index year were considered "metabo

116 mellitus is the consequence of the diabetic dyslipidaemia, in particular post-prandial lipaemia, and

117 Primary dyslipidaemias, including familial hypercholesterolaemia

118 cluding smoking, hypertension, diabetes, and dyslipidaemia-increased.

119 pertensive drugs and concurrent treatment of dyslipidaemia, insulin resistance, diabetes and inflamma

120 Dyslipidaemia is a hallmark of chronic kidney disease (C

121 Diabetic dyslipidaemia is an important risk factor and is open to

122 Dyslipidaemia is an important risk factor for cardiovasc

123 Management of dyslipidaemia is crucial for the reduction in the risk o

124 retroviral therapy for at least 6 months and dyslipidaemia (LDL cholesterol 3.4-5.7 mmol/L and trigly

125 In the first study, 50 patients with dyslipidaemia (LDL-C 100-190 mg/dL; 40 active, 10 placeb

126 Age, family history, Fasting Blood Glucose, dyslipidaemia, lipid profile, parity and use of oral con

127 Individuals with mixed dyslipidaemia may require combination therapy to achieve

128 , hypertension, smoking, poor diet, obesity, dyslipidaemia, metabolic syndrome, low physical activity

129 esity, impairment of glucose metabolism, and dyslipidaemia; musculoskeletal disorders, such as myopat

130 cipation, whilst higher levels of adiposity, dyslipidaemia, neuroticism, Alzheimer's and schizophreni

131 The severity of dyslipidaemia not only correlates with CKD stage but is

132 ncreased blood pressure, insulin resistance, dyslipidaemia, obesity and mesenteric artery endothelial

133 malities such as dysfunctional adiposity and dyslipidaemia occur without detectable organ damage; Sta

134 CKD-associated dyslipidaemia occurs as a consequence of complex interac

135 f alirocumab and evolocumab in patients with dyslipidaemia or atherosclerotic cardiovascular disease.

136 omplicated obesity or BMI 27-45 kg/m(2) with dyslipidaemia or hypertension were eligible for enrolmen

137 erolaemia or any condition causing secondary dyslipidaemia, or a history of statin intolerance, diabe

138 alcoholic steatohepatitis (NASH), hereditary dyslipidaemia, or cryptogenic cirrhosis.

139 Patients with dyslipidaemia, osteoporosis, and metabolic disorders wer

140 e--ie, the roles of hyperglycaemia, diabetic dyslipidaemia (other than the control of LDL-cholesterol

141 e modifiable risk factors (ie, hypertension, dyslipidaemia, overweight, smoking cigarettes, and low p

142 gestational diabetes mellitus, obesity, and dyslipidaemia (P < .01).

143 ardless of TG/LDL-C, in both the general and dyslipidaemia populations (RMSE = 11.45/9.20 mg/dL; R(2)

144 Secondary analyses were conducted within dyslipidaemia populations of each database.

145 (POR 0.36, 95% CI 0.32 to 0.40, p < 0.001), dyslipidaemia (POR 0.33, 95% CI 0.14 to 0.80, p = 0.010)

146 n total cholesterol and lipid fractions, and dyslipidaemias prevalence in Latin America and the Carib

147 ese results may help strengthen programs for dyslipidaemias prevention/management in LAC.

148 the risk of hypertension, hyperglycaemia and dyslipidaemia, recognized as the metabolic syndrome.

149 Dyslipidaemia remains a significant risk factor for card

150 BMI differentially increase hypertension or dyslipidaemia risk in people with HIV receiving INSTIs,

151 ults reiterate the need for hypertension and dyslipidaemia screening in people with HIV.

152 Localized dyslipidaemia, secondary to cholestasis, was investigate

153 only coexists with Type 2 diabetes, obesity, dyslipidaemia, sedentary lifestyle, and smoking leading

154 While obesity, dyslipidaemia, smoking, and insulin resistance are major

155 re drugs available to test the hypothesis of dyslipidaemias-specific prevention of electrophysiologic

156 to direct LDL-C measurement, irrespective of dyslipidaemia status.

157 In the dyslipidaemia study, one patient withdrew consent and on

158 as a potential therapeutic target to control dyslipidaemia that may introduce a new avenue for preven

159 LDL triglyceride levels for the treatment of dyslipidaemias that increase cardiovascular disease risk

160 reciated that inflammatory mechanisms couple dyslipidaemia to atheroma formation.

161 the programme: hypertension, heart failure, dyslipidaemia, type 2 diabetes, asthma, or breast cancer

162 for the treatment or prevention of adult HIV dyslipidaemia, versus no or other intervention were incl

163 Early identification of primary dyslipidaemias via lipid clinic referral optimises patie

164 Dyslipidaemia was found in 69.4% of patients, 60% of FDR

165 Similarly, dyslipidaemia was more common in participants using teno

166 e of hypertension, diabetes, overweight, and dyslipidaemia was similar in both groups.

167 e, sex, body mass index, type 2 diabetes and dyslipidaemia, we observed that cardiac impairment was a

168 rtension, diabetes, myocardial infarction or dyslipidaemia were not.

169 Drugs for hyperglycaemia, hypertension, and dyslipidaemia were prescribed by protocol.

170 recently only diabetic patients with marked dyslipidaemia were routinely offered lipid-lowering ther

171 2 months, exhibiting insulin resistance, and dyslipidaemia were used in this study.

172 hypertension, diabetes, smoking, obesity and dyslipidaemia) were present among 17.5% (95% confidence

173 h, high total cholesterol levels, indicating dyslipidaemia, were associated with decreased IFN-gamma,

174 specific lipoprotein pattern termed 'uraemic dyslipidaemia', which is characterized by rather normal

175 zheimer's disease, obesity, osteoporosis and dyslipidaemia with a single FSH-blocking agent.

176 by dietary supplementation and mitigation of dyslipidaemia with myriocin both alleviate neuropathy in

177 Treatment of dyslipidaemia with statins has been challenging in peopl

178 of tenofovir alafenamide was associated with dyslipidaemia, with the latter association partly mediat